XML 142 R51.htm IDEA: XBRL DOCUMENT
v3.20.1

Goodwill (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2019
Goodwill |
Schedule of details of and movement in goodwill | Details of and movement in this caption of the consolidated balance sheet at 31 December 2018 were as follows:
|  |  |  | Thousands of Euros
|  |  |  | Balance at |  | Business |  |  |  | Translation |  | Balance at
|  | Segment |  | 31/12/2017 |  | Combination |  | Disposals |  | differences |  | 31/12/2018
Net value |  |  |  |  |  |  |  |  |  |  |  |
Grifols UK.Ltd. (UK) |  | Bioscience |  | 7,745 |  | — |  | — |  | (63) |  | 7,682
Grifols Italia.S.p.A. (Italy) |  | Bioscience |  | 6,118 |  | — |  | — |  | — |  | 6,118
Biomat USA, Inc.(USA) |  | Bioscience |  | 205,254 |  | 42,780 |  | (2,827) |  | 9,907 |  | 255,114
Grifols Australia Pty Ltd. (Australia) / Medion Diagnostics AG (Switzerland) |  | Diagnostic |  | 9,543 |  | — |  | — |  | (272) |  | 9,271
Grifols Therapeutics, Inc. (USA) |  | Bioscience |  | 1,852,905 |  | — |  | — |  | 87,871 |  | 1,940,776
Araclon Biotech, S.L. (Spain) |  | Diagnostic |  | 6,000 |  | — |  | — |  | — |  | 6,000
Progenika Biopharma, S.A. (Spain) |  | Diagnostic |  | 40,516 |  | — |  | — |  | — |  | 40,516
Grifols Diagnostic (Novartis & Hologic) (USA, Spain and Hong Kong) |  | Diagnostic |  | 2,435,907 |  | — |  | — |  | 114,349 |  | 2,550,256
Kiro Grifols S.L. (Spain) |  | Hospital |  | 26,510 |  | (2,134) |  | — |  | — |  | 24,376
Goetech LLC (USA) |  | Hospital |  | — |  | 55,321 |  | — |  | 3,624 |  | 58,945
Haema AG (Germany) |  | Bioscience |  | — |  | 171,134 |  | — |  | — |  | 171,134
Biotest Pharma Corp (USA) |  | Bioscience |  | — |  | 136,234 |  | — |  | 2,808 |  | 139,042
|  |  |  | 4,590,498 |  | 403,335 |  | (2,827) |  | 218,224 |  | 5,209,230
|  |  |  | (See note 3) |  |  |  |  |  |  |  |
Details of and movement in this caption of the consolidated balance sheet at 31 December 2019 are as follows:
|  |  |  | Thousands of Euros
|  |  |  | Balance at |  | Business |  | Translation |  | Balance at
|  | Segment |  | 31/12/2018 |  | Combination |  | differences |  | 31/12/2019
Net value |  |  |  |  |  |  |  |  |  |
Grifols UK.Ltd. (UK) |  | Bioscience |  | 7,682 |  | — |  | 425 |  | 8,107
Grifols Italia.S.p.A. (Italy) |  | Bioscience |  | 6,118 |  | — |  | — |  | 6,118
Biomat USA, Inc.(USA) |  | Bioscience |  | 255,114 |  | (4,278) |  | 5,060 |  | 255,896
Grifols Australia Pty Ltd. (Australia) / Medion Diagnostics AG (Switzerland) |  | Diagnostic |  | 9,271 |  | — |  | 201 |  | 9,472
Grifols Therapeutics, Inc. (USA) |  | Bioscience |  | 1,940,776 |  | — |  | 38,902 |  | 1,979,678
Araclon Biotech, S.L. (Spain) |  | Diagnostic |  | 6,000 |  | — |  | — |  | 6,000
Progenika Biopharma, S.A. (Spain) |  | Diagnostic |  | 40,516 |  | — |  | — |  | 40,516
Grifols Diagnostic (Novartis & Hologic) (USA, Spain and Hong Kong) |  | Diagnostic |  | 2,550,256 |  | — |  | 50,694 |  | 2,600,950
Kiro Grifols S.L. (Spain) |  | Hospital |  | 24,376 |  | — |  | — |  | 24,376
Goetech LLC (USA) |  | Hospital |  | 58,945 |  | — |  | 1,181 |  | 60,126
Haema AG (Germany) |  | Bioscience |  | 171,134 |  | 18,880 |  | — |  | 190,014
Biotest Pharma Corp (USA) |  | Bioscience |  | 139,042 |  | 10,943 |  | 2,963 |  | 152,948
Interstate Blood Bank, Inc. (USA) |  | Bioscience |  | — |  | 172,663 |  | 199 |  | 172,862
|  |  |  | 5,209,230 |  | 198,208 |  | 99,625 |  | 5,507,063
|  |  |  |  |  | (See note 3) |  |  |  |
Schedule of key assumptions used in calculating impairment of CGUs | The key assumptions used in calculating impairment testing of the CGUs for 2018 were as follows:
|  | Perpetual Growth rate |  | Pre-tax discount rate |
Bioscience |  | 2 | % | 8.90 | %
Diagnostic |  | 2 | % | 9.40 | %
Hospital |  | 1.50 | % | 13.10 | %
The key assumptions used in calculating impairment testing of the CGUs for 2019 have been as follows:
|  | Perpetual Growth rate |  | Pre-tax discount rate |  | EBITDA multiple
Bioscience |  | 2 | % | 8.80 | % | —
Diagnostic |  | — |  | — |  | 14.5x
Hospital |  | 1.50 | % | 10.80 | % | —
Schedule of reasonably possible changes in key assumptions considered in the calculation of the CGUs' recoverable amount |
|  | Perpetual Growth rate |  | Pre-tax discount rate |  | EBITDA margin
Bioscience |  | +/- 50 bps |  | +/- 50 bps |  | —
Diagnostic |  | — |  | — |  | +/- 250 bps
Hospital |  | +/- 50 bps |  | +/- 50 bps |  | —

X
- Definition The disclosure of key assumptions used in calculating impairment of cash generating units (CGUs). + References No definition available. + Details
Name: | grfs_DisclosureOfAssumptionsUsedInCalculatingImpairmentOfCashGeneratingUnitsTableTextBlock
Namespace Prefix: | grfs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of detailed information about sensitivity analysis for recoverable amount of the cash generating units. + References No definition available. + Details
Name: | grfs_ScheduleOfReasonablyPossibleChangesInKeyAssumptionsConsideredInCalculationOfCguSRecoverableAmountTableTextBlock
Namespace Prefix: | grfs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of the reconciliation of changes in goodwill. [Refer: Goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph B67 -Subparagraph d -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration